Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00618
|
|||||
| Drug Name |
Vandetanib
|
|||||
| Synonyms |
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; AZD-6474; CH 331; CH-331; F9995-0087; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; Vandetanib (JAN/INN); Vandetanib (Pan-TK inhibitor); Vandetanib [INN]; Vandetanib, Zactima, ZD6474; ZD 6474; ZD-6474; ZD6474; Zactima; Zactima, ZD6474
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Thyroid gland tumours [ICD11: 2D10] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H24BrFN4O2
|
|||||
| Canonical SMILES |
CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
|
|||||
| InChI |
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
|
|||||
| InChIKey |
UHTHHESEBZOYNR-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 443913-73-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 475.4 | Topological Polar Surface Area | 59.5 | ||
| Heavy Atom Count | 30 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
4.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103194628
, 103905338
, 111682639
, 12015522
, 123110212
, 124756961
, 124772087
, 124893337
, 124893338
, 125163767
, 125350704
, 126619162
, 126651857
, 126661732
, 126731545
, 127330006
, 127330007
, 131333378
, 131408693
, 134339002
, 134964431
, 135228305
, 135685324
, 135685325
, 135685344
, 135697656
, 135727395
, 14716916
, 14761077
, 36412170
, 46394288
, 47208064
, 49742597
, 50068212
, 50100123
, 50112766
, 50599279
, 53789193
, 57354678
, 8030012
, 8034317
, 85246147
, 91147360
, 92721418
, 93309619
, 93581029
, 93692935
, 9471114
, 99436956
, 99445235
|
|||||
| ChEBI ID |
ChEBI:49960
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
| References | ||||||
| 1 | Vandetanib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46. | |||||
| 3 | Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.